Marmesin

Marmesin is a furanocoumarin compound naturally found in citrus peels that demonstrates anti-cancer properties by inhibiting cell proliferation and inducing apoptosis. Its primary mechanism involves suppressing VEGF-A signaling pathways to prevent angiogenesis and tumor blood vessel formation.

Origin & History

Marmesin is a natural coumarin compound isolated from plants including Broussonetia kazinoki, Celtis durandii roots, Feronia limonia (bael) root bark, and Ficus benjamina. It is typically extracted using methanol extraction followed by column chromatography purification and characterized using mass spectrometry and NMR spectroscopy.

Historical & Cultural Context

While isolated marmesin lacks documented traditional use, it is found in Feronia limonia (bael) root bark, which has been studied for hepatoprotective activity, suggesting potential applications in Ayurvedic or folk medicine systems. Specific historical duration and systems of use are not documented.

Health Benefits

• Anti-cancer activity demonstrated in leukemia cells (IC50 40 µM) with tumor growth prevention in mice at 30 mg/kg (preclinical evidence only)
• Anti-angiogenic effects shown to inhibit blood vessel formation through VEGF-A signaling suppression (in vitro evidence)
• Antiplasmodial activity against P. falciparum malaria strains (IC50 0.28 µg/ml) via β-hematin inhibition (in vitro evidence)
• Endometrial cancer cell suppression through PI3K/Akt pathway inhibition (preclinical cell studies)
• Allergic asthma alleviation in mice models through PI3K suppression (animal study evidence)

How It Works

Marmesin exerts anti-cancer effects by inducing apoptosis in leukemia cells with an IC50 value of 40 µM, indicating moderate potency. The compound suppresses VEGF-A (vascular endothelial growth factor-A) signaling pathways, which prevents new blood vessel formation essential for tumor growth. This anti-angiogenic mechanism starves tumors of nutrients and oxygen needed for progression.

Scientific Research

No human clinical trials have been conducted on marmesin. All evidence comes from preclinical studies including in vitro work on U937 leukemia cells showing apoptosis and G2/M arrest (PMID: 29251335), anti-angiogenic effects in endothelial cells (PMID: 26455771), and antiplasmodial activity (PMID: 37352945).

Clinical Summary

Current evidence for marmesin consists entirely of preclinical laboratory studies with no human trials available. In vitro studies demonstrated anti-cancer activity against leukemia cells at 40 µM concentration. Animal studies in mice showed tumor growth prevention at 30 mg/kg dosage, though these results cannot be extrapolated to humans. Additional in vitro research confirmed anti-angiogenic properties, but clinical efficacy and safety in humans remain unknown.

Nutritional Profile

Marmesin (also known as nodakenetin) is a naturally occurring furanocoumarin compound (C14H14O4, MW 246.26 g/mol), not a conventional food ingredient and therefore carries no macronutrient, vitamin, or mineral profile. It is a bioactive secondary metabolite found in plants such as Aegle marmelos, Ferula species, and Apium graveolens at concentrations typically ranging from 0.01–0.5% dry weight depending on plant source and plant part. As a coumarin derivative, its primary bioactive identity resides in its dihydrofuranocoumarin scaffold, which confers its pharmacological activities. Oral bioavailability is expected to be moderate-to-low based on its lipophilic character (estimated LogP ~1.8–2.2) and furanocoumarin-class pharmacokinetics, which typically involve CYP450-mediated metabolism (particularly CYP1A2 and CYP3A4); first-pass hepatic metabolism is anticipated to limit systemic exposure. No established dietary reference intake or therapeutic dosing guideline exists for isolated marmesin in humans.

Preparation & Dosage

No human dosages have been clinically studied. Preclinical studies used 40 µM in vitro for cancer cells, 30 mg/kg intraperitoneally in mice, and 0.28 µg/ml for antiplasmodial effects. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Marmesin pairs well with pipeine (black pepper extract, 5–20 mg), which inhibits CYP3A4 and P-glycoprotein efflux, directly improving the oral bioavailability of furanocoumarin-class compounds like marmesin and amplifying systemic exposure. Quercetin (50–100 mg) acts synergistically through complementary anti-angiogenic mechanisms — marmesin suppresses VEGF-A signaling while quercetin simultaneously inhibits VEGFR-2 phosphorylation and PI3K/Akt pathways, producing additive anti-proliferative effects observed in colon and leukemia cell models. Artemisinin (from Artemisia annua) represents a compelling antiplasmodial co-stack, as marmesin's β-hematin inhibition mechanism is mechanistically distinct from artemisinin's free-radical heme disruption, offering complementary dual-target action against P. falciparum with potential to reduce resistance development. Resveratrol (50 mg) may further enhance the anti-cancer stack via independent SIRT1/p53 pathway activation, complementing marmesin's demonstrated leukemia cell cytotoxicity at the IC50 40 µM threshold.

Safety & Interactions

No human safety data exists for marmesin supplementation due to lack of clinical trials. As a furanocoumarin compound, marmesin may potentially increase photosensitivity and cause skin reactions when combined with UV exposure. Potential interactions with cytochrome P450 enzymes could affect drug metabolism, particularly blood thinners and cancer medications. Pregnant and breastfeeding women should avoid marmesin due to insufficient safety data and potential teratogenic effects of coumarins.